FLXN Flexion Therapeutics Inc.

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

The presentation will be available through an on-demand webcast beginning at 7 a.m. ET on September 13, 2021, and will be accessible on the Flexion website at .

About Flexion Therapeutics

Flexion Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of people with musculoskeletal conditions, beginning with osteoarthritis, the most common form of arthritis. The company's core values are focus, ingenuity, tenacity, transparency and fun. Please visit .

Contact:

Scott Young

Vice President, Corporate Communications & Investor Relations

Flexion Therapeutics, Inc.

T: 781-305-7194



EN
08/09/2021

Underlying

FLXNFlexion Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Flexion Therapeutics Inc.

 PRESS RELEASE
Free
FLXN Flexion Therape...

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding L...

Pacira BioSciences to Acquire Flexion Therapeutics Further Expanding Leadership Position in Non-Opioid Pain Management -- Adds highly complementary ZILRETTA® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- -- Further enhances topline revenue growth; provides attractive potential synergies and expected to be accretive to full-year 2022 earnings and significantly accretive thereafter -- -- Pacira to host conference call today at 8:30 AM ET -- TAMPA, Fla. and BURLINGTON, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- (Nas...

October 11, 2021 1 EN
 PRESS RELEASE
Free
FLXN Flexion Therape...

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Ru...

Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BURLINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to three new employees consisting of 6,315 restricted stock units. The Compensation Committee of the Board of Directors approved the grants with an effective date of October 1, 2021. The restricted stock units were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted sto...

October 1, 2021 1 EN
 PRESS RELEASE
Free
FLXN Flexion Therape...

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Glo...

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The presentation will be available through an on-demand webcast beginning at 7 a.m. ET on September 13, 2021, and will be accessible on the Flexion website at . Ab...

September 8, 2021 1 EN
 PRESS RELEASE
Free
FLXN Flexion Therape...

Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Health...

Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside chat is scheduled to begin at 4:35 p.m. ET on Thursday, September 9, 2021. To access the live webcast of the presentation, please visit the Flexion website at . About Flexion TherapeuticsFlexion Therapeut...

September 3, 2021 1 EN
 PRESS RELEASE
Free
FLXN Flexion Therape...

Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Acad...

Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee AAOS finds that ZILRETTA (triamcinolone acetonide extended-release injectable suspension) can improve patient outcomes over immediate-release corticosteroids BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its...

September 2, 2021 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch